CLINICAL TRIALS PROFILE FOR AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

All Clinical Trials for amoxicillin; clarithromycin; vonoprazan fumarate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Heze Municipal 3rd people's hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Jining No.2 People's Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Maternity and Child Care Health Center of Dezhou	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	PKUcare luzhong hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qihe County City Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qilu Hospital of Shandong University	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Clinical Trial Conditions for amoxicillin; clarithromycin; vonoprazan fumarate

Condition Name

Condition Name for amoxicillin; clarithromycin; vonoprazan fumarate
Intervention	Trials
Helicobacter Pylori Infection	2

Condition MeSH

Condition MeSH for amoxicillin; clarithromycin; vonoprazan fumarate
Intervention	Trials

Clinical Trial Locations for amoxicillin; clarithromycin; vonoprazan fumarate

Trials by Country

Trials by Country for amoxicillin; clarithromycin; vonoprazan fumarate
Location	Trials
China	3

Clinical Trial Progress for amoxicillin; clarithromycin; vonoprazan fumarate

Clinical Trial Phase

Clinical Trial Phase for amoxicillin; clarithromycin; vonoprazan fumarate
Clinical Trial Phase	Trials
Phase 4	2

Clinical Trial Status

Clinical Trial Status for amoxicillin; clarithromycin; vonoprazan fumarate
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for amoxicillin; clarithromycin; vonoprazan fumarate

Sponsor Name

Sponsor Name for amoxicillin; clarithromycin; vonoprazan fumarate
Sponsor	Trials
Maternity and Child Care Health Center of Dezhou	2
PKUcare luzhong hospital	2
Shandong University	2

Sponsor Type

Sponsor Type for amoxicillin; clarithromycin; vonoprazan fumarate
Sponsor	Trials
Other	21

Clinical Trials, Market Analysis, and Projections for Amoxicillin, Clarithromycin, and Vonoprazan Fumarate

Introduction

The combination of amoxicillin, clarithromycin, and vonoprazan fumarate is a significant therapeutic approach, particularly in the treatment of Helicobacter pylori (H. pylori) infections and other gastrointestinal disorders. Here, we will delve into the current clinical trials, market analysis, and future projections for these drugs.

Clinical Trials and Efficacy

Amoxicillin and Ceftriaxone Synergy

While amoxicillin is commonly used, its synergy with other antibiotics like ceftriaxone has been explored. A study on Listeria monocytogenes showed a synergistic effect between amoxicillin and ceftriaxone, suggesting potential alternative treatments for severe infections like listeriosis[1].

Clarithromycin in Combination Therapy

Clarithromycin is often used in combination with vonoprazan and amoxicillin for treating H. pylori infections. This triple therapy has been shown to be effective in eradicating the bacteria and is recommended for patients with this condition[3].

Vonoprazan Fumarate in Clinical Trials

Vonoprazan fumarate, a potassium-competitive acid blocker, has been extensively studied for its efficacy in treating acid-related disorders such as gastroesophageal reflux disease (GERD), stomach ulcers, and H. pylori infections. Clinical trials have demonstrated its rapid action and potential for fewer side effects compared to traditional proton pump inhibitors (PPIs)[2].

Market Analysis

Current Market Landscape

The global pharmaceutical market is substantial, with a value of $1.475 trillion in 2022 and a projected CAGR of 5% over the next six years[5].

Vonoprazan Fumarate Market

The market for vonoprazan fumarate is growing, driven by increasing incidence of acid-related disorders and the need for more effective and rapid-acting medications. Key players in this market include METROCHEM API PRIVATE LTD, AMI LIFESCIENCES PRIVATE LTD, OPTIMUS DRUGS PRIVATE LTD, and BEIJING THTD PHARMACEUTICAL TECHNOLOGY CO LTD[5].

Clarithromycin Market

Clarithromycin, being a macrolide antibiotic, has a broad range of applications including respiratory tract infections, skin infections, and H. pylori treatment. Its market is stable, with ongoing demand due to its efficacy in various bacterial infections[3].

Amoxicillin Market

Amoxicillin, a widely used antibiotic, has a large market share due to its broad-spectrum activity and affordability. It is often prescribed for a variety of bacterial infections and is a key component in combination therapies[1].

Market Drivers and Opportunities

Increasing Healthcare Spending

The expansion of healthcare coverage globally and rising disposable income in developing regions are driving the market for these drugs. This increased spending on healthcare solutions is expected to boost the adoption of amoxicillin, clarithromycin, and vonoprazan fumarate[2].

Positive Clinical Trial Outcomes

Positive outcomes from clinical trials, such as the efficacy of vonoprazan fumarate in treating acid-related disorders, enhance confidence and adoption among healthcare professionals. This is a significant driver for the market growth of these drugs[2].

Co-Marketing Partnerships

Potential co-marketing partnerships and integrations with telehealth platforms can enhance brand visibility and product uptake in key markets. These strategies are expected to further drive the market growth of these medications[2].

Market Challenges and Restraints

Competitive Environment

The pharmaceutical market is highly competitive, with numerous drugs available for similar indications. This competition can limit the market share of specific drugs like vonoprazan fumarate, despite their unique benefits[2].

Regulatory and Technological Constraints

Regulatory hurdles and technological constraints can delay innovation and limit the expansion of these drugs into new markets. Ensuring compliance with regulatory requirements and investing in R&D are crucial to overcoming these challenges[2].

Future Projections

Growth Trajectory

The market for vonoprazan fumarate is expected to grow robustly, driven by rising consumer awareness, escalating healthcare spending, and favorable regulatory pathways. The global market for pharmaceutical-grade vonoprazan fumarate is forecasted to expand significantly over the next few years[5].

Antibiotic Pipeline and Resistance

The future of antibiotics, including those used in combination with vonoprazan fumarate, is critical due to the rising issue of antibiotic resistance. Effective pull incentives and investments in R&D are necessary to strengthen the antibiotic pipeline and ensure the availability of effective treatments in the future[4].

Key Takeaways

• Synergistic Effects: The combination of amoxicillin and ceftriaxone shows synergistic effects against certain bacterial infections, offering potential alternative treatments.
• Clinical Efficacy: Clarithromycin, in combination with vonoprazan and amoxicillin, is effective in treating H. pylori infections.
• Market Growth: The market for vonoprazan fumarate is growing due to its efficacy in treating acid-related disorders and the need for rapid-acting medications.
• Challenges: The pharmaceutical market faces challenges such as competition, regulatory hurdles, and technological constraints.
• Future Outlook: The market is expected to grow, driven by increasing healthcare spending and favorable regulatory environments.

FAQs

What is the primary use of the combination of amoxicillin, clarithromycin, and vonoprazan fumarate?

The primary use of this combination is to treat Helicobacter pylori (H. pylori) infections.

How does vonoprazan fumarate differ from traditional proton pump inhibitors (PPIs)?

Vonoprazan fumarate is a potassium-competitive acid blocker that offers faster relief and potentially fewer side effects compared to traditional PPIs.

What are the key drivers of the market for these drugs?

Key drivers include increasing healthcare spending, positive clinical trial outcomes, and favorable regulatory pathways.

What challenges does the market for these drugs face?

The market faces challenges such as a competitive environment, regulatory hurdles, and technological constraints.

How is the future of the antibiotic pipeline expected to evolve?

The future of the antibiotic pipeline depends on effective pull incentives and investments in R&D to address the issue of antibiotic resistance and ensure a robust pipeline of new antibiotics[4].

Last updated: 2024-12-31